Literature DB >> 8673700

Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement.

P S Linsley1, J Bradshaw, J Greene, R Peach, K L Bennett, R S Mittler.   

Abstract

T lymphocyte receptor CTLA-4 binds costimulatory molecules CD80 (B7-1) and CD86 (B7-2) with high avidity and negatively regulates T cell activation. CTLA-4 functions at the cell surface, yet is primarily localized in intracellular vesicles. Here, we demonstrate cycling of CTLA-4 between intracellular stores and the cell surface. Intracellular vesicles containing CTLA-4 overlapped with endocytic compartment(s) and with perforin-containing secretory granules. Cell surface expression of CTLA-4 was rapidly increased by raising intracellular calcium levels. During T cell activation, intracellular and cell surface CTLA-4 became focused towards sites of TCR activation. Cycling and directional control of CTLA-4 expression may regulate its functional interaction with APCs bearing peptide-MHC complexes of appropriate specificity and avidity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8673700     DOI: 10.1016/s1074-7613(00)80480-x

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  184 in total

1.  Study of the interaction of the medium chain mu 2 subunit of the clathrin-associated adapter protein complex 2 with cytotoxic T-lymphocyte antigen 4 and CD28.

Authors:  E R Follows; J C McPheat; C Minshull; N C Moore; R A Pauptit; S Rowsell; C L Stacey; J J Stanway; I W Taylor; W M Abbott
Journal:  Biochem J       Date:  2001-10-15       Impact factor: 3.857

Review 2.  CD28, CTLA-4 and their ligands: who does what and to whom?

Authors:  D M Sansom
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

Review 3.  CTLA-4 and tolerance: the biochemical point of view.

Authors:  Shunsuke Chikuma; Jeffrey A Bluestone
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 4.  Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy.

Authors:  Michael Postow; Margaret K Callahan; Jedd D Wolchok
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

5.  Thymocyte development is normal in CTLA-4-deficient mice.

Authors:  C A Chambers; D Cado; T Truong; J P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

6.  Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein.

Authors:  Y Zhang; J P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

Review 7.  Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition).

Authors:  Jun Guo; Shukui Qin; Jun Liang; Tongyu Lin; Lu Si; Xiaohong Chen; Zhihong Chi; Chuanliang Cui; Nan Du; Yun Fan; Kangsheng Gu; Fang Li; Junling Li; Yongheng Li; Houjie Liang; Jiwei Liu; Man Lu; Aiping Lu; Kejun Nan; Xiaohui Niu; Hongming Pan; Guoxin Ren; Xiubao Ren; Yongqian Shu; Xin Song; Min Tao; Baocheng Wang; Wenbin Wei; Di Wu; Lingying Wu; Aiwen Wu; Xiaolin Xu; Junyi Zhang; Xiaoshi Zhang; Yiping Zhang; Huiyan Zhu
Journal:  Ann Transl Med       Date:  2015-12

8.  FOXP3, CBLB and ITCH gene expression and cytotoxic T lymphocyte antigen 4 expression on CD4(+) CD25(high) T cells in multiple sclerosis.

Authors:  F Sellebjerg; M Krakauer; M Khademi; T Olsson; P S Sørensen
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

9.  CD40L is transferred to antigen-presenting B cells during delivery of T-cell help.

Authors:  Jennifer L Gardell; David C Parker
Journal:  Eur J Immunol       Date:  2016-11-28       Impact factor: 5.532

10.  CD4+CD28- costimulation-independent T cells in multiple sclerosis.

Authors:  S Markovic-Plese; I Cortese; K P Wandinger; H F McFarland; R Martin
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.